Slynd for Perimenopause: What the Drospirenone-Only Pill Does and Doesn't Do

The short answer

The reason it keeps surfacing in perimenopause conversations is that it solves two problems at once for a specific group of women in their forties: it provides contraception (still needed until menopause is confirmed) without estrogen, and its 24+4 schedule tends to produce a more predictable bleeding pattern than the older continuous progestin-only "mini-pills." Two features separate it from those older pills. First, published reviews of the drospirenone-only pill describe it as inhibiting ovulation rather than relying primarily on cervical mucus thickening. Second, the label allows a full 24-hour margin on a missed dose before backup contraception is required, instead of the much narrower same-time-every-day window that defines the traditional norethindrone mini-pill.

What Slynd will not do is replace estrogen. The 2022 hormone therapy position statement of The North American Menopause Society identifies systemic estrogen therapy as the most effective treatment for vasomotor symptoms, and the separate 2020 NAMS position statement on genitourinary syndrome of menopause places low-dose vaginal estrogen at the centre of treating vaginal and urinary symptoms. A progestin-only contraceptive is neither of those things. If your dominant complaint is hot flashes, night sweats, sleep disruption from vasomotor symptoms, or vaginal dryness and painful sex, Slynd is not the drug that addresses them — and choosing it because it sounds "hormonal" is a common and costly mismatch.

What Slynd actually contains and how it is taken

Slynd is a single-agent oral contraceptive. Each active tablet contains 4 mg of drospirenone, a synthetic progestin structurally derived from spironolactone, and there is no estrogen component of any kind. Packs are arranged as 24 white active tablets followed by 4 green inert tablets, taken one per day continuously, with a new pack started immediately after the last inert tablet. That 24+4 structure is deliberate and is what distinguishes it from the older progestin-only pills, which are taken every day with no hormone-free interval at all.

The drospirenone dose is worth pausing on. Drospirenone is more familiar as one half of a combined pill, where it is paired with an estrogen. Slynd uses it alone, at 4 mg, with no estrogen — a progestin dose deployed to do work that estrogen would otherwise share. Published reviews of the drospirenone-only pill in the 24+4 regimen describe the dose as chosen to achieve reliable ovulation inhibition while the four inert days allow a predictable withdrawal bleed for many users.

Practically, this means Slynd behaves less like a mini-pill and more like a stripped-down combined pill without the estrogen. It is taken at roughly the same time each day, it produces a scheduled bleeding window in many users, and it does not require the near-military timing precision that gave older progestin-only pills their reputation.

One detail that matters for anyone switching: there is no placebo-week gap between packs. The four green tablets are the gap. Skipping them and running packs back to back is not what the label describes, and doing so changes the bleeding pattern in ways your prescriber should be part of deciding.

How it differs from the older progestin-only mini-pill

The traditional progestin-only pill in the United States contains norethindrone, is taken continuously with no inactive tablets, and demands that each dose be taken within a narrow window of the same time daily. Miss that window and backup contraception is needed. That rigidity exists because the norethindrone mini-pill works substantially through cervical mucus effects that wane quickly, and it does not consistently suppress ovulation across all users.

Slynd's design targets exactly that weakness. Reviews of the drospirenone-only pill describe ovulation inhibition as the primary mechanism, and describe pharmacodynamic work in which deliberately delayed doses did not produce the rapid loss of ovulation suppression seen with older progestin-only formulations. The label reflects this: backup contraception is directed when a white active tablet is taken more than 24 hours late.

For a 44-year-old juggling shift work, travel across time zones, or simply an unpredictable evening, the difference between a window measured in a few hours and a full 24-hour margin is not a technicality. It is the difference between a method that fails in real life and one that tolerates it.

The second structural difference is the hormone-free interval. Continuous norethindrone produces no scheduled bleed and frequently produces unpredictable spotting. The four inert days in Slynd create a defined window in which bleeding is expected, which is why it is often described as offering better cycle predictability than its predecessors.

What the FDA label approves — and what it does not

The Slynd prescribing information states a single indication: use by females of reproductive potential to prevent pregnancy. That is the entire approved scope. There is no approved indication for heavy menstrual bleeding, for cycle regulation, for acne, for premenstrual symptoms, for perimenopausal symptom control, or for endometrial protection alongside estrogen therapy.

This distinction is not pedantry. When a drug is used off-label, the safety and efficacy data supporting that specific use may be thinner than the data behind the approved use, insurance coverage may be harder to obtain, and the prescriber is exercising clinical judgment rather than following a label. All of that can still be entirely reasonable — off-label prescribing is common and often evidence-informed — but you are entitled to know which side of the line you are standing on.

In particular, Slynd is not approved as the progestogen component of menopausal hormone therapy. If someone is taking systemic estrogen and still has a uterus, the progestogen used to protect the endometrium is a specific decision with its own evidence base, and NAMS addresses endometrial protection directly in its 2022 hormone therapy position statement. Assuming that a contraceptive progestin-only pill automatically covers that requirement is not a safe assumption to make on your own.

If a clinician does recommend Slynd during perimenopause, the useful questions are: what specifically are we treating, is that use on-label or off-label, and what will tell us in three months whether it worked.

Why Slynd comes up so often in perimenopause discussions

Perimenopause creates an awkward overlap. Fertility declines but does not disappear, so contraception is still needed — ACOG's patient guidance on the menopause years is explicit that pregnancy remains possible until periods have stopped for a full year. At the same time, cycles become erratic, bleeding can become heavier or closer together, and many women in their forties acquire reasons to avoid estrogen: migraine with aura, hypertension, smoking, elevated clotting risk, or simply a preference.

Slynd sits precisely in that gap. It is an estrogen-free method that still suppresses ovulation, which means it addresses contraception and, off-label, tends to impose more order on an unruly cycle than doing nothing does. For someone who wants one pill to cover birth control while cycles are misbehaving, and who cannot or does not want to take estrogen, the appeal is obvious.

There is a second, subtler reason it circulates in perimenopause forums: the older progestin-only pills were widely disliked for their timing rigidity and their unpredictable spotting, and combined pills are often declined or contraindicated after 40. Slynd occupies territory that was previously thin.

What it does not do is diagnose or track your menopausal transition. Because the drospirenone-only pill suppresses ovulation, hormone testing while taking it is not a reliable way to establish where you are in the transition — and ACOG frames the diagnosis of menopause as clinical, based on 12 consecutive months without a period, rather than a lab value. Being on a pill that removes your natural bleeding pattern removes the main signal you would otherwise be reading.

Slynd is contraception, not hormone therapy

This is the single most consequential distinction on this page. Menopausal hormone therapy and hormonal contraception are different drug classes used at different doses for different purposes, and the fact that both involve sex steroids does not make them interchangeable.

The 2022 NAMS hormone therapy position statement identifies systemic estrogen therapy as the most effective treatment for vasomotor symptoms — hot flashes and night sweats — and for the bone loss of menopause, with the treatment decision individualized by age, time since menopause, and personal risk. Slynd contains no estrogen. It cannot deliver any of that. If you start it hoping the night sweats will settle, you have chosen a drug with no mechanism for the thing you are treating.

The same applies to genitourinary symptoms. The 2020 NAMS position statement on genitourinary syndrome of menopause addresses vaginal dryness, burning, urinary symptoms, and pain with sex, and low-dose vaginal estrogen therapy is central to that discussion. A systemic progestin-only contraceptive is not a treatment for those symptoms, and vaginal dryness that emerges while taking it will not resolve because of it.

The reverse mismatch matters too: menopausal hormone therapy is not contraception. Standard HT doses are not designed or approved to prevent pregnancy. Someone in perimenopause on HT who could still conceive needs a contraceptive method as well. Confusing the two directions costs people either symptom relief or an unplanned pregnancy, and both happen.

The bleeding pattern reality

The most honest thing anyone can tell you about Slynd is that unscheduled bleeding is common, particularly in the first several packs, and it is the most frequent reason people stop taking it. Published descriptions of the drospirenone-only pill in the 24+4 regimen report that unscheduled bleeding and spotting are frequent early and tend to decline over successive cycles, while the four inert days produce a scheduled bleeding episode for a substantial share of users.

Tend to decline is not the same as will resolve. Some people settle into a predictable pattern by the third or fourth pack. Some continue to spot. Some stop bleeding almost entirely. All three are documented outcomes, and none of them can be predicted for an individual before starting.

The practical implication is that judging Slynd after one month is judging it too early, and judging it after six months of unrelenting spotting is judging it fairly. A reasonable plan is to give it three to four full packs before concluding anything, while keeping a simple record of bleeding days — a note on your phone is enough — so that the conversation at follow-up is based on data rather than recollection.

Perimenopause adds a complication that does not exist for a 25-year-old on the same pill. Bleeding changes in your forties can come from the pill, from the transition itself, or from something else entirely — fibroids, polyps, endometrial hyperplasia, or cancer. ACOG's guidance on perimenopausal bleeding treats new heavy bleeding, bleeding between periods, and bleeding after sex as findings that warrant evaluation. Starting a pill does not exempt you from that. If anything, it makes the record-keeping more important, because you need to be able to describe what changed and when.

The potassium question: what drospirenone actually does

Drospirenone is derived from spironolactone and shares some of its antimineralocorticoid activity, which means it can promote sodium and water excretion and potassium retention. At 4 mg this is a real pharmacologic property, not a footnote, and the Slynd prescribing information addresses it directly with a hyperkalemia warning.

The label's concern is concentrated in two groups. The first is people with conditions that predispose to high potassium — renal impairment, hepatic impairment, or adrenal insufficiency, which appear among the contraindications. The second is people taking chronic daily long-term treatment with medications that raise serum potassium, for whom the label advises considering a serum potassium check during the first treatment cycle. Those medications include ACE inhibitors, angiotensin receptor blockers, aldosterone antagonists, potassium-sparing diuretics, potassium supplementation, heparin and related agents, and NSAIDs taken chronically.

That NSAID entry catches more people than expected. Occasional ibuprofen for a headache is not the scenario the label is describing; daily NSAID use for arthritis, back pain, or chronic migraine is. Daily anti-inflammatory use is easy to overlook precisely because it is bought over the counter and never feels like a prescription-level interaction — and this is a case where it belongs on the list you hand your clinician.

The action item is unglamorous and specific: bring a complete medication list, including over-the-counter and supplement use, and ask directly whether your combination triggers the label's first-cycle potassium check. If it does, that is a single blood draw, not a reason to abandon the method.

Who should not take Slynd

The prescribing information lists contraindications that rule the drug out regardless of how appealing the rest of its profile is. Renal impairment is one, driven by the potassium consideration. Adrenal insufficiency is another, for the same reason. Liver disease, including benign or malignant liver tumors, is a contraindication.

Undiagnosed abnormal uterine bleeding is on that list, and it deserves emphasis in a perimenopause context. If you are bleeding abnormally and no one has established why, the answer is not to start a pill and see whether it settles. Starting hormonal treatment over an unevaluated bleeding pattern can delay the diagnosis of endometrial pathology, and ACOG's guidance on perimenopausal bleeding exists precisely because that pattern of delay causes harm. Evaluate first, treat second.

Progestin-sensitive cancers, current or historical, are also contraindicated. Because the label's contraindication list is specific and not something to reconstruct from memory, ask your prescriber or pharmacist to check it against your own history rather than relying on any summary, including this one.

Beyond formal contraindications, there is a question of fit. If your leading complaints are hot flashes, sleep disruption from night sweats, or vaginal dryness, Slynd is the wrong tool even if you have no contraindication to it at all. Being eligible for a drug is not a reason to take it.

Drug interactions worth checking before you start

Drospirenone is metabolized in a way that makes it vulnerable to enzyme induction, and the label warns that drugs or herbal products which induce certain enzymes may decrease the effectiveness of hormonal contraceptives or cause breakthrough bleeding. The classic inducers are rifampin and related antimycobacterials, several anticonvulsants used for both epilepsy and migraine prophylaxis, some antiretrovirals, and St. John's wort.

That last one is the trap. St. John's wort is sold over the counter as a mood supplement, is commonly taken by people navigating perimenopausal mood changes, and is a genuine enzyme inducer. Someone can be taking it for exactly the symptoms that brought them to their clinician while quietly undermining the contraceptive they were just prescribed.

In the other direction, strong inhibitors of the same enzymes can increase drospirenone exposure, which is relevant given the potassium considerations described above. The label addresses concomitant use with such agents, and this is a case where the interaction check should be done by the prescriber or pharmacist with your full list in front of them rather than by searching one drug at a time.

The potassium-raising interaction list from the previous section overlaps with common cardiovascular prescriptions. If you take a blood pressure medication, verify which class it is. ACE inhibitors and ARBs are widely prescribed in this age group and both appear in the label's potassium discussion.

How long contraception is actually needed in perimenopause

The reason this question keeps recurring is that erratic cycles feel like the end of fertility long before it arrives. ACOG's patient guidance on the menopause years defines menopause as 12 consecutive months without a menstrual period, and pregnancy remains possible during the transition up to that point. Skipped periods, longer gaps, and hot flashes are all compatible with an ovulatory cycle sneaking through.

Taking a hormonal contraceptive complicates the assessment, because the pill supplies its own bleeding pattern. You cannot count 12 period-free months while a pill is determining when you bleed, and because the drospirenone-only pill suppresses ovulation, hormone levels drawn while on it do not give a clean read on your ovarian status either.

This means the exit strategy has to be planned rather than improvised. The usual approach is a conversation with your clinician about age, symptom pattern, and risk of pregnancy, and a deliberate decision about when to stop and what, if anything, to observe afterward. It is not a decision to make alone based on how you feel, and it is worth raising at a routine visit rather than waiting until a pack runs out.

If contraception is the only reason you are taking Slynd and you want a method that does not require this calculus, that is a legitimate thing to say out loud. Different methods have different exit properties, and the right answer for the last five years before menopause is not automatically the same as the right answer for the previous twenty.

What Slynd does not address, and what does

Vasomotor symptoms. Hot flashes and night sweats are not treated by a progestin-only contraceptive. The 2022 NAMS hormone therapy position statement identifies systemic hormone therapy as the most effective option for these symptoms, with the decision individualized to your age, time since menopause, and risk profile. If vasomotor symptoms are your main problem, that is the conversation to have.

Genitourinary symptoms. Vaginal dryness, burning, urinary urgency, and pain with sex fall under genitourinary syndrome of menopause, addressed by the 2020 NAMS position statement on GSM. Local vaginal therapy is central to that discussion and is a different treatment from anything a contraceptive pill provides. Slynd will not fix vaginal dryness, and dryness that appears while you are on it should be treated on its own terms.

Abnormal bleeding of unknown cause. This needs a diagnosis first. ACOG's guidance on perimenopausal bleeding describes when bleeding warrants evaluation, and its committee opinion on transvaginal ultrasonography addresses the role of imaging in evaluating the endometrium in women with postmenopausal bleeding. Suppressing a bleeding pattern before knowing its cause is the wrong sequence.

Painful periods. Dysmenorrhea has its own management pathway, described in ACOG's patient guidance on painful periods, and while hormonal contraception features in that discussion generally, Slynd is not approved for it and you should know you are choosing an off-label route if that is the goal.

None of this makes Slynd a bad drug. It makes it a specific drug. The failure mode to avoid is treating it as a general-purpose hormonal solution for a phase of life rather than as a contraceptive with a favorable dosing window and no estrogen.

A practical way to evaluate whether it fits your situation

Start by naming the problem in one sentence. If that sentence is "I need reliable contraception and I cannot or prefer not to take estrogen," Slynd is squarely in scope and the rest of the assessment is about contraindications and interactions. If the sentence is "my cycles are chaotic and I want them predictable," it is a plausible off-label option to discuss. If the sentence involves hot flashes, night sweats, or vaginal dryness, you are in the wrong aisle.

Then assemble two lists before the appointment. The first is every medication and supplement you take, including over-the-counter NSAIDs, potassium supplements, and anything herbal — St. John's wort specifically. The second is your kidney, liver, and adrenal history, plus any history of progestin-sensitive cancer, because those determine eligibility outright.

Third, describe your current bleeding pattern precisely, including how it has changed over the past year. If anything in that description is new heavy bleeding, bleeding between periods, or bleeding after sex, that needs evaluation before a pill is started, not after.

Finally, set a review point. Three to four packs is a reasonable interval at which to decide whether the bleeding pattern is heading somewhere acceptable. Put it in the calendar when you start, so the decision is made deliberately instead of drifting for a year.

This site does not sell or prescribe anything. If you want to see which telehealth and in-person options handle perimenopausal care, compare providers and bring the questions below to whichever one you choose.

Questions to ask your clinician

Bring these to your appointment — they turn a vague visit into a decision.

• Is prescribing Slynd for my situation on-label or off-label, and what exactly are we trying to change?
• I take these medications and supplements — does any combination trigger the label's first-cycle potassium check?
• My kidney, liver, and adrenal history is this. Does anything in it rule Slynd out for me?
• My bleeding has changed in this specific way over the past year. Should that be evaluated before I start any hormonal pill?
• If hot flashes or night sweats are my main problem, is Slynd the right drug, or should we be discussing hormone therapy instead?
• How many packs should I give this before we decide whether the bleeding pattern is acceptable, and when should I come back?
• How will we decide when I can stop contraception altogether, given that the pill controls my bleeding pattern?

Frequently asked questions

Is Slynd approved for perimenopause?

No. The FDA prescribing information for Slynd lists a single indication: use by females of reproductive potential to prevent pregnancy. Using it for cycle control, bleeding management, or symptom smoothing during perimenopause is off-label. Off-label prescribing is legal and often clinically reasonable, but you should know which category your prescription falls into and ask your clinician to confirm it.

Will Slynd help with hot flashes?

No. Slynd contains no estrogen, and vasomotor symptoms respond to estrogen. The 2022 NAMS hormone therapy position statement identifies systemic hormone therapy as the most effective treatment for hot flashes and night sweats. A progestin-only contraceptive has no mechanism for relieving them, and starting one in hope of vasomotor relief is a common mismatch.

How is Slynd different from the traditional mini-pill?

Three ways. Slynd's progestin is drospirenone at 4 mg rather than norethindrone. Its label allows a 24-hour margin on a late dose before backup contraception is needed, a far wider window than the narrow same-time-daily precision the norethindrone mini-pill requires. And it uses a 24+4 regimen with four inert tablets that create a scheduled bleeding window, whereas the traditional mini-pill is taken continuously with no hormone-free interval.

Can Slynd be used as the progestogen part of hormone therapy?

It is not approved for that. Slynd's label covers contraception only, with no indication for endometrial protection alongside estrogen therapy. If you are taking systemic estrogen and still have a uterus, the progestogen component is a specific decision addressed in the NAMS 2022 hormone therapy position statement, and it should be made by your clinician rather than assumed from a contraceptive prescription.

Why does Slynd have a potassium warning?

Drospirenone is derived from spironolactone and shares antimineralocorticoid activity, meaning it can promote potassium retention. The label carries a hyperkalemia warning and advises considering a serum potassium check during the first treatment cycle in people on chronic daily long-term treatment with potassium-raising drugs — including ACE inhibitors, ARBs, aldosterone antagonists, potassium-sparing diuretics, potassium supplements, heparin, and chronically used NSAIDs. Renal impairment, hepatic impairment, and adrenal insufficiency are contraindications.

How long does the spotting last after starting Slynd?

Unscheduled bleeding and spotting are common in the early packs and, in published descriptions of the drospirenone-only pill, tend to decline over successive cycles. That is a trend, not a promise — some people settle into a predictable pattern, some continue to spot, some stop bleeding almost entirely, and none of it is predictable in advance. Three to four full packs is a fair interval before deciding whether the pattern is acceptable.

Can I tell if I have reached menopause while taking Slynd?

Not reliably. ACOG frames menopause as a clinical diagnosis based on 12 consecutive months without a period, and while a pill is determining when you bleed, you cannot count those months. Because the drospirenone-only pill suppresses ovulation, hormone testing on it does not give a clean read on ovarian status either. Plan the stopping decision with your clinician rather than trying to infer it from how you feel.

Do I still need contraception in my late forties?

Yes, until menopause is established. ACOG's patient guidance on the menopause years states that pregnancy remains possible during the transition, and that menopause is defined by 12 consecutive months without a period. Skipped cycles, longer gaps, and hot flashes all coexist with occasional ovulation, so irregularity by itself is not evidence that contraception is no longer needed.

What happens if I take a Slynd tablet late?

The label allows a 24-hour margin. If an active white tablet is taken more than 24 hours late, the instruction is to take it as soon as remembered, continue the pack at the usual time, and use a backup non-hormonal method for the next seven days. This is a substantially wider window than the narrow same-time-daily requirement of the norethindrone mini-pill, which is the main practical reason people switch.

Should I start Slynd if my bleeding has recently become heavier?

Not before that bleeding is evaluated. Undiagnosed abnormal uterine bleeding is a contraindication in the Slynd label, and ACOG's guidance treats new heavy bleeding, bleeding between periods, and bleeding after sex as findings that warrant assessment. Starting hormonal treatment over an unevaluated pattern can mask and delay the diagnosis of endometrial pathology. Get the cause established first.

Primary sources

1. FDA prescribing information, Slynd (drospirenone) 4 mg tablets, 2019.
2. Drospirenone 4 mg-only pill (DOP) in a 24+4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol, 2020. PMID 32538188.
3. Oestrogen-free oral contraception with a 4 mg drospirenone-only pill. Eur J Contracept Reprod Health Care, 2020. PMID 32312141.
4. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022. PMID 35797481.
5. The 2020 genitourinary syndrome of menopause position statement of NAMS. Menopause, 2020. PMID 32852449.
6. ACOG: Perimenopausal Bleeding and Bleeding After Menopause (patient FAQ).
7. ACOG Committee Opinion: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding.
8. ACOG: The Menopause Years (patient FAQ).
9. ACOG: Dysmenorrhea — Painful Periods (patient FAQ).